Harrow Health has finalized an agreement to acquire commercial rights for MAQ-100 in the United States and Canada from Wakamoto Pharmaceutical, according to a press release.
MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection, is marketed in Japan as MaQaid and was originally launched for visualization during vitrectomy. It has since gained indications for the treatment of diabetic macular edema, macular edema associated with retinal vein occlusion and noninfectious uveitis, the release said.
Harrow plan to use the clinical data that supported the approval of MaQaid in